<DOC>
	<DOCNO>NCT01227928</DOCNO>
	<brief_summary>This study determine whether therapy pazopanib effective safe Asian woman epithelial ovarian , fallopian tube primary peritoneal cancer whose cancer progress first-line chemotherapy .</brief_summary>
	<brief_title>Efficacy Safety Pazopanib Monotherapy After First-line Chemotherapy Ovarian , Fallopian Tube , Primary Peritoneal Cancer Asian Women</brief_title>
	<detailed_description>This study extension study VEG110655 study . The parent study , VEG110655 , design evaluate whether pazopanib 800 mg daily 52 week prolong progression free survival ( PFS ) woman diagnose ovarian , fallopian tube primary peritoneal cancer . These woman obtain stable disease , complete remission , partial remission debulking surgery least five cycle chemotherapy ( taxane/platinum ) . This extension study evaluate safety efficacy outcomes pazopanib monotherapy placebo Asian population indication parent study .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>write informed consent At least 18 year old . Histologically confirm , International Federation Gynecology Obstetrics ( FIGO ) stage IIIV epithelial ovarian , fallopian tube primary peritoneal carcinoma treat surgical debulking least five cycle platinumtaxane doublet chemotherapy . Study randomization least 3 week 12 week date last chemotherapy dose , major toxicity previous chemotherapy must resolve . No evidence disease progression Eastern Cooperative Oncology Group ( ECOG ) performance status less equal 2 Able swallow retain oral medication . Adequate hematologic , hepatic , renal system function follow : Hematologic Absolute neutrophil count ( ANC ) least 1.5 X 10^9/L Hemoglobin least 9 g/dL ( 5.59 mmol/L ) Platelets least 100 X 10^9/L Prothrombin time ( PT ) international normalize ratio ( INR ) 1.2 X ULN Activated partial thromboplastin time ( aPTT ) 1.2 X ULN Hepatic Total bilirubin 1.5 X ULN AST ALT 2.5 X ULN Renal Serum creatinine 1.5 mg/dL Or , great 1.5 mg/dL : Calculated creatinine clearance least 50 mL/min Urine Protein Urine protein 0 , trace , +1 determine dipstick urinalysis , &lt; 1.0 gram determine 24hour urine protein analysis . Nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) OR childbearing potential , agree use adequate contraception . Either ( ) bulky disease , ( b ) residual disease opinion investigator need imminent secondline therapy Synchronous primary endometrial carcinoma , past history primary endometrial carcinoma , exclude unless certain condition meet . Clinically significant gastrointestinal abnormality Prolongation correct QT interval ( QTc ) &gt; 480 msecs History one cardiovascular condition within past 6 month prior randomization Poorly control hypertension History cerebrovascular accident ( include transient ischemic attack ) , pulmonary embolism untreated deep venous thrombosis ( DVT ) within past 6 month prior randomization Major surgery ( include interval debulking ) trauma within 28 day , minor surgical procedure within 7 day , prior randomization , nonhealing wound , fracture , ulcer . Evidence active bleeding bleed diathesis . Hemoptysis within 6 week prior randomization . Endobronchial metastasis . Serious and/or unstable preexist medical ( e.g. , uncontrolled infection ) , psychiatric , condition could interfere subject 's safety , provision inform consent , compliance study procedure . Investigational antiVEGF anticancer therapy prior study randomization . Known immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate pazopanib . Prior concurrent invasive malignancy currently within last 5 year show/ed activity disease ( except ovarian , fallopian tube , peritoneal cancer , concurrent endometrial cancer FIGO stag IA/B )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>tyrosine kinase inhibitor</keyword>
	<keyword>Primary Peritoneal Carcinoma</keyword>
	<keyword>primary peritoneal cancer</keyword>
	<keyword>ovarian cancer</keyword>
	<keyword>Fallopian Tube Cancer</keyword>
	<keyword>gynecologic cancer</keyword>
	<keyword>anti-angiogenesis</keyword>
	<keyword>pazopanib</keyword>
</DOC>